Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147 - Wikidata - awgldk - TriplyDB

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147

http://www.wikidata.org/entity/Q33947880

about

Implications of mismatch repair-deficient status on management of early stage colorectal cancer BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies The role of N-glycans in colorectal cancer progression: potential biomarkers and therapeutic applications BRAF Mutation in Colorectal Cancer: An Update New and emerging factors in tumorigenesis: an overview Different treatment strategies and molecular features between right-sided and left-sided colon cancers Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells Microsatellite instability testing and its role in the management of colorectal cancer.Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients.A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer.Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.Current and future biomarkers in colorectal cancer.Precision Nutrition for Targeting Lipid Metabolism in Colorectal Cancer.microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.Association between clinicopathological characteristics and RAS mutation in colorectal cancer.Polo-like kinase 2 promotes chemoresistance and predicts limited survival benefit from adjuvant chemotherapy in colorectal cancer.One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status.Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study Eastern Canadian Colorectal Cancer Consensus Conference 2017 Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017 Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer

P2860

Q26772272-ABB554D1-4CD9-4CA4-A58E-245F922D718B Q26772276-AD0E6679-CD2E-416A-99A3-DC4D3D1A349C Q26779166-E6D5988F-CAAD-4B6C-95FD-2E98ED5F81DE Q26781926-3F617C00-0580-4DCC-BDD0-DD1CF6BE0F9C Q26801253-F8F4C2A3-D637-42DE-B94A-5A8779CE29E8 Q26865322-60D699A1-FBE0-4969-8083-2C871064F6C7 Q27027648-50B60226-FEC3-431B-9321-C51ADCB5870D Q34502713-EDB62529-5B26-491F-86F5-2537468A73BA Q35163670-E7FE45F0-F9A0-49D2-B5B0-41C6746101D1 Q35579056-DF0C0972-F4DA-42FC-8AC9-B091EB26FAE7 Q36103110-E92A9321-2912-422F-BDF6-D4D4C0D82072 Q36124008-6AE47249-E7AD-4850-A39C-81D493A5240E Q36167042-FA695425-95E5-4F0D-834E-9575B1679CAB Q36201032-C8D684D5-1C4C-4AAA-B0C9-2BC2F35EBDBC Q36340970-94AE8E47-EB16-4585-935E-FF371D190B88 Q36352341-720EA1D1-8A3C-44DB-8372-1AA3C86BAB2B Q36393095-D0F07252-CC74-4C6B-8143-90BEE662EDE1 Q36465989-F127BCEF-E7A1-411B-B93E-65B3CDB58BBF Q36472959-DB8AAABD-255B-46A2-B005-CCBA2DF9F61B Q38652294-23423062-5916-48CC-B201-9C17CCADACA9 Q38727912-19881014-618F-4FEC-884E-14F7A435F79D Q38792393-9F0C7B2E-819B-45A7-80FD-EAB42DC20D40 Q39038413-FBA7847C-5FD3-4AE7-94F0-DFBAA237243A Q40087648-C3AD4F2F-88B1-49F7-8CA0-CA93174908C7 Q40125078-C6F42B2E-CE1B-4BCA-BDB5-7F9AD44B7BE1 Q40752079-4FEFDD04-CDF9-4EA9-970C-E2EED6567958 Q43492228-0435C6FA-A8F9-4727-93BA-832C530EA182 Q45258328-DE1A893D-BA7D-4DCC-9DD9-61190EF313F6 Q47128749-B87F6D76-724F-4C87-87F0-44E2EE09B8E5 Q48010330-6056A0D5-CEF9-43BD-BA1A-EF218232B293 Q52641338-09E918A8-D897-42AF-9E36-E71DC0645601 Q55362939-01D45463-B36D-488C-988B-5614E8E0C1ED Q58608206-800C0ED1-5EF1-4BF5-BDE4-BFBF11DD806E Q58783221-99F26AD1-AB49-40D2-8E72-715E28688CB7 Q58783248-66F9453D-C02C-44C2-A3D9-59C07DAC38B4 Q58806326-C59768FE-954D-4599-A718-74FD68024E7A

P2860

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147

http://www.wikidata.org/entity/Q33947880

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Patient and tumor characterist ...... n cancer, NCCTG/Alliance N0147

@ast

Patient and tumor characterist ...... n cancer, NCCTG/Alliance N0147

@en

type

label

Patient and tumor characterist ...... n cancer, NCCTG/Alliance N0147

@ast

Patient and tumor characterist ...... n cancer, NCCTG/Alliance N0147

@en

prefLabel

Patient and tumor characterist ...... n cancer, NCCTG/Alliance N0147

@ast

Patient and tumor characterist ...... n cancer, NCCTG/Alliance N0147

@en

P1433

Q33947880-36A8C44A-45D2-4DD3-A006-E975FDBAC916

P1476

Q33947880-AA124392-68E1-4906-A247-8C94C378D23A

P2093

Q33947880-0276C907-AA01-4142-9BB5-48429CEC484A

Q33947880-12286505-322B-47A7-AFFF-E978501EB326

Q33947880-164C2FCF-DDDD-4907-B46C-5F4110D4022E

Q33947880-18D9B154-8987-4B9D-AD5B-E3E61D2EC552

Q33947880-2DD9DA37-08CB-492E-9C9A-D1750C556742

Q33947880-4D5D9D58-ED31-4994-A11B-4523873CA6AE

Q33947880-5BAD0DCE-2F01-4565-9497-5BB2FA44188C

Q33947880-7EB634F4-9214-420C-B768-168B36277F77

Q33947880-91E27828-64AC-4935-B5D5-67A4DA2F5307

Q33947880-A7FF98B4-92F8-4872-9FEF-1A696800CDE1

P2860

Q33947880-0CC6873D-0C81-43D7-A194-E62EA7A15B68

Q33947880-0F16B1D7-16CE-4A08-BA22-26250A9764D4

Q33947880-0F9A87BE-F7E0-41B4-8486-6E1762DC4DC5

Q33947880-12DF7E4B-2986-4730-B6F2-18184BCAA2DE

Q33947880-2523D40D-6269-4149-9F5D-ACCE2F793BDC

Q33947880-306A4491-8648-4413-91E0-C85A501A050C

Q33947880-34F74D14-688D-4E87-BF3D-2F307DEB602E

Q33947880-3C11D354-2A0A-45EA-8420-E97452ED0DD6

Q33947880-4DC6F460-905F-4609-98E9-10FA81CEC015

Q33947880-5303CB6C-45A7-4075-AEAE-50EE3E998B5F

P31

Q33947880-D0AFC53B-2A39-4BA6-84A9-807A177A51C2

P356

Q33947880-174723C6-87CD-4E10-942A-F5AD5E3261F2

P407

Q33947880-7C64EC28-63EB-4F7D-9580-0F326F6331F3

P433

Q33947880-A4DF8B54-0856-4758-8209-96BA9644721E

P478

Q33947880-857C9EF6-1824-4BE5-A389-7B5CC5B4D7E9

P577

Q33947880-EE81D63B-4B94-4094-B940-B0342AEC44AC

P698

Q33947880-6C051F04-FEB6-4463-9491-E62081C93A4E

P921

Q33947880-C7A4FF48-E2C0-4AAC-BD5D-AE1AC00693DE

P932

Q33947880-30B7F2DE-8274-44E7-9CED-B5D17CB7970B

P356

P1433

Journal of the National Cancer Institute

P1476

Patient and tumor characterist ...... n cancer, NCCTG/Alliance N0147

@en

P2093

Alliance for Clinical Trials in Oncology

http://www.w3.org/2001/XMLSchema#string

Axel Grothey

http://www.w3.org/2001/XMLSchema#string

Daniel J Sargent

http://www.w3.org/2001/XMLSchema#string

Emily Chan

http://www.w3.org/2001/XMLSchema#string

Frank A Sinicrope

http://www.w3.org/2001/XMLSchema#string

Garth D Nelson

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Berenberg

http://www.w3.org/2001/XMLSchema#string

Joleen M Hubbard

http://www.w3.org/2001/XMLSchema#string

Michelle R Mahoney

http://www.w3.org/2001/XMLSchema#string

Paul J Limburg

http://www.w3.org/2001/XMLSchema#string

P2860

CpG island methylator phenotype in colorectal cancer

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Cancer statistics, 2013

CpG-rich islands and the function of DNA methylation

Lifestyle factors and Ki-ras mutations in colon cancer tumors

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Genetic alterations during colorectal-tumor development

P31

scholarly article

P356

10.1093/JNCI/DJU106

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24925349

http://www.w3.org/2001/XMLSchema#string

P921

P932

4110470

http://www.w3.org/2001/XMLSchema#string